The aim of the present study was to assess the impact of MBS on major cardiovascular adverse events (MACE) in patients with severe obesity and T2D compared to patients with T2D treated with GLP-1 RA. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.